Cell and gene therapies offer promise, but face market access challenges

In light of the progress and potential of cell and gene therapies, Amy Grogg, senior vice president of strategy and communication at US drug wholesale company AmerisourceBergen (NYSE: ABC), considers the strategies needed to overcome challenges around market access and the complexity of commercialization in an expert view column.

Over the next 10 years, the cell and gene therapy pipeline is projected to produce thousands of targeted, potentially curative therapies.

Fueled by medical advances and significant investments in research and development, these personalized therapies – comprised of living cells or genetic materials – could revolutionize how we treat diseases.